Handelsavisen
prelaunch
Companies Healthcare EKF.L
EK
EKF.L London Stock Exchange Advanced Medical Equipment & Technology

EKF Diagnostics Holdings PLC

$25,55
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

EKF Diagnostics Holdings PLC develops, manufactures, and distributes diagnostic products and systems for use in clinical and point-of-care settings.

Business. EKF Diagnostics Holdings PLC (EKF.L) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. It is headquartered in the United Kingdom and is primarily listed on the London Stock Exchange. Specific details regarding operating segments or geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target34,67

Analyst recommendations

3 analysts · consensus Buy
Buy3
Hold0
Sell0
12-month price target
34,67
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
3 analysts · indicative
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EKF.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EKF.L. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    EKF Diagnostics Holdings PLC (EKF.L) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. It is headquartered in the United Kingdom and is primarily listed on the London Stock Exchange. Specific details regarding operating segments or geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    EKF Diagnostics has a fully diluted share count of 430.9 million, with no dilution observed between basic and diluted shares, indicating no material dilution risk from stock options or convertible instruments. The company's liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents.

    The company's profitability and return metrics are not available in the valuation snapshot, precluding a direct comparison to industry_config preferred metrics or cohort medians. However, the absence of liquidity risk and the low dilution potential suggest a stable capital structure.

    EKF Diagnostics' revenue concentration by segment and geography is not disclosed in the available data. The company operates in the healthcare equipment industry, which is typically diversified across multiple therapeutic areas and geographies, but specific segment or regional breakdowns are not available.

    The company's growth trajectory is not quantified in the outlook data, but analyst price targets suggest a consensus view of moderate upside, with a mean target of 34.67 GBP and a median of 35.00 GBP. Analysts have issued one strong-buy and two buy recommendations, with no holds or sells, indicating a generally positive sentiment.

    The company's risk assessment highlights a low dilution potential and no near-term dilution sources identified in the source documents. However, the lack of liquidity risk assessment introduces uncertainty about the company's ability to meet short-term obligations.

    No recent events, such as filings or transcripts, are available in the source documents to inform the company's current strategic or operational direction.

    Key takeaways
    • EKF Diagnostics has no dilution risk as of the latest data, with basic and diluted shares outstanding being equal.
    • Analysts have a generally positive outlook, with a mean price target of 34.67 GBP and a median of 35.00 GBP.
    • The company's liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
    • No recent events or filings are available to assess the company's strategic direction.
    • The company's profitability and return metrics are not available for comparison to industry benchmarks.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2026-03-24
    FY 2026 · Full-year highlights

    Revenue £51.6M, +2,7% YoY; Operating income +11,5% YoY.

    Revenue£51.6M+2,7 % YoY
    Operating income£7.0M+11,5 % YoY
    Net income£2.1M−66,0 % YoY
    Free cash flow£5.6M−34,9 % YoY
    EPS
    Operating cash flow£9.7M−28,9 % YoY
    Financials
    Income statement
    Revenue£51.6M
    Gross profit£26.5M
    Operating income£7.0M
    Net income£2.1M
    Margins
    Gross margin51.4%
    Operating margin13.5%
    Net margin4.1%
    FCF margin10.8%
    Balance sheet
    Total assets£81.1M
    Total liabilities£12.1M
    Total equity£69.0M
    Cash & equivalents
    Long-term debt£1.4M
    Cash flow
    Operating cash flow£9.7M
    CapEx-£2.4M
    Free cash flow£5.6M
    SBC
    P&L flow · revenue → net income
    Revenue £51.6MOperating costs £44.6MTax £4.9MNet income £2.1M
    Highlights
    • Revenue £51.6M, +2,7% YoY
    • Operating income +11,5% YoY
    • Net income −66,0% YoY
    • Free cash flow −34,9% YoY
    • Net margin 4.1%

    Valuation FY

    Market price
    $25,55
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,02
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-11 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,02
    Revenueno estimateno estimate54,6M GBP
    Operating incomeno estimateno estimate9,7M GBP
    Full-year consensus mean (period as reported by source) · consensus in GBP. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy1
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$34,67 · Median $35,00
    Low $34,00High $35,00
    Operating income · consensus9,7M GBP
    EPS surprise
    −71,4 %
    reported vs consensus · miss
    Revenue surprise
    −5,6 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$34,00
    Mean$34,67
    Median$35,00
    High$35,00
    Spot$25,55
    +35.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • EKF Diagnostics Holdings PLC Market data — financials · 2026-05-27
    • EKF Diagnostics Holdings PLC Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EKF.LCanonical
    London Stock Exchange · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-06-20 00:43 UTCANALYSTAnalyst coverage initiated
    2026-03-24 07:00 UTCEARNINGSAnnual results — FY 2026 Revenue GBP 51.6M · Net GBP 2.1M
    2025-03-25 07:00 UTCEARNINGSAnnual results — FY 2025 Revenue GBP 50.2M · Net GBP 6.2M
    2024-03-20 08:30 UTCEARNINGSAnnual results — FY 2024 Revenue GBP 52.6M · Net GBP 2.4M
    2023-03-28 07:00 UTCEARNINGSAnnual results — FY 2023 Revenue GBP 66.6M · Net GBP -10.1M
    2022-03-29 07:00 UTCEARNINGSAnnual results — FY 2022 Revenue GBP 81.8M · Net GBP 15.9M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage